KRAS and non-small cell lung carcinoma: The predictive value of KRAS mutations in NSCLC was investigated in patients receiving definitive chemotherapy (56), postoperative radiotherapy adjuvant chemotherapy (57), or the phase III TRIBUTE trial comparing first-line carboplatin/paclitaxel with erlotinib or placebo for advanced NSCLC (58).